ブロダルマブの第4相臨床試験

基本情報

NCT ID

NCT04183881

ステータス

完了

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

138

治験依頼者名

Kyowa Kirin Co., Ltd.

概要

This study \[4827-005 (post market)\] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003 (Study 003) and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004). 4827-005 study was conducted as phase 3 clinical trial until July 4th 2016 (approval date in Japan). After that date 4827-005 study was switched to phase 4 study.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)